Regístrese
Buscar en
Enfermedades Infecciosas y Microbiología Clínica
Toda la web
Inicio Enfermedades Infecciosas y Microbiología Clínica Daptomicina en las infecciones por bacterias grampositivas en pacientes oncohema...
Información de la revista
Vol. 30. Núm. S1.
Daptomicina en las infecciones causadas por bacterias grampositivas
Páginas 43-49 (Febrero 2012)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 30. Núm. S1.
Daptomicina en las infecciones causadas por bacterias grampositivas
Páginas 43-49 (Febrero 2012)
DOI: 10.1016/S0213-005X(12)70071-X
Acceso a texto completo
Daptomicina en las infecciones por bacterias grampositivas en pacientes oncohematológicos y en receptores de trasplante
Daptomycin in Gram-positive bacterial infections in oncohematological patients and transplant recipients
Visitas
2485
Jordi Carratalàa,
Autor para correspondencia
jcarratala@ub.edu

Autor para correspondencia.
, Óscar Lenb, Julián de la Torre-Cisnerosc
a Servicio de Enfermedades Infecciosas, Hospital Universitari de Bellvitge-IDIBELL, Universitat de Barcelona, L'Hospitalet de Llobregat, Barcelona, España
b Servicio de Enfermedades Infecciosas, Hospital Universitari Vall d’Hebron-VHIR, Barcelona, España
c Unidad de Gestión Clínica de Enfermedades Infecciosas, Hospital Universitario Reina Sofía-IMIBIC, Universidad de Córdoba, Córdoba, España
Este artículo ha recibido
2485
Visitas
Información del artículo
Resumen

Las infecciones por bacterias grampositivas son una causa importante de morbilidad y mortalidad en los pacientes oncohematológicos y en los receptores de trasplante. Los estafilococos coagulasa negativa, Staphylococcus aureus, Enterococcus spp. y los estreptococos del grupo viridans son los organismos grampositivos aislados con mayor frecuencia. La resistencia antibiótica en estos organismos es un problema en aumento y supone un reto terapéutico. Daptomicina es un antibiótico con una rápida actividad bactericida, de amplio espectro frente a bacterias grampositivas, incluidas las cepas resistentes a otros fármacos. En este artículo se revisan algunos aspectos de las infecciones por organismos grampositivos en estos pacientes inmunodeprimidos y se analiza con detalle la experiencia con daptomicina en el tratamiento de tales infecciones.

Palabras clave:
Neutropenia
Trasplante de progenitores hematopoyéticos
Trasplante de órgano sólido
Bacterias grampositivas
Bacteriemia
Daptomicina
Abstract

Gram-positive infections are a major cause of morbidity and mortality in oncohematological patients and transplant recipients. The most frequently isolated Gram-positive organisms are the coagulase-negative staphylococci, Staphylococcus aureus and Enterococcus spp., and viridans group streptococci. Antibiotic resistance in these organisms is increasing and poses a challenge to clinicians. Daptomycin is rapidly bactericidal against a broad spectrum of gram-positive bacteria, including strains resistant to other drugs. The present article reviews some aspects of Gram-positive infections in these immunocompromised patients and provides a detailed analysis of experience with daptomycin in the treatment of these infections.

Keywords:
Neutropenia
Hematopoietic stem cell transplantation
Solid organ transplantation
Gram-positive bacteria
Bacteremia
Daptomycin
El Texto completo está disponible en PDF
Bibliografía
[1.]
C. Cervera, A. Moreno.
Infección bacteriana.
Infeciones en pacientes trasplantados,
[2.]
J.J. Snyder, A.K. Israni, Y. Peng, L. Zhang, T.A. Simon, B.L. Kasiske.
Rates of first infection following kidney transplant in the United States.
Kidney Int, 75 (2009), pp. 317-326
[3.]
Y.J. Kim, S.I. Kim, S.H. Wie, Y.R. Kim, J.A. Hur, J.Y. Choi, et al.
Infectious complications in living-donor liver transplant recipients: a 9-year single center experience.
Transpl Infect Dis, 10 (2008), pp. 316-324
[4.]
J. Gavaldà, A. Román.
Infección en el trasplante de pulmón.
Enferm Infecc Microbiol Clin, 25 (2007), pp. 639-650
[5.]
H. Wisplinghoff, H. Seifert, R.P. Wenzel, M.B. Edmond.
Current trends in the epidemiology of nosocomial bloodstream infections in patients with haematological malignancies and solid neoplasms in hospitals in the United States.
Clin Infect Dis, 36 (2003), pp. 1103-1110
[6.]
S. Yamasaki, Y. Heike, S. Mori, T. Fukuda, D. Maruyama, R. Kato, et al.
Infectious complications in chronic graft-versus-host disease: a retrospective study of 145 patients of allogeneic hematopoietic stem cell transplantation with reduced-and conventional-intensity conditioning regimens.
Transpl Infect Dis, 10 (2008), pp. 252-259
[7.]
A. Moreno, C. Cervera, J. Gavaldá, M. Rovira, R. De la Cámara, I. Jarque, et al.
Bloodstrem infections among transplant recipients: results of a nationwide surveillance in Spain.
Am J Transplant, 7 (2007), pp. 2579-2586
[8.]
C. Cervera, A. Moreno.
Infecciones en el paciente con trasplante renal y pancreático.
Enferm Infecc Microbiol Clin, 25 (2007), pp. 345-355
[9.]
N. Fernández-Sabé, C. Cervera, F. López-Medrano, M. Llano, E. Sáez, O. Len, et al.
Risk factors, clinical features, and outcomes of listeriosis in solid-organ transplant recipients: a matched case-control study.
Clin Infect Dis, 49 (2009), pp. 1153-1159
[10.]
J.M. Aguado, A. García-Reyne, C. Lumbreras.
Infecciones en los pacientes trasplantados de hígado.
Enferm Infecc Microbiol Clin, 25 (2007), pp. 401-410
[11.]
R. San-Juan, J.M. Aguado, C. Lumbreras, J. Fortún, O. Len, P. Muñoz, et al.
Selective intestinal decontamination with fluoroquinolones for the prevention of early bacterial infections after liver transplantation.
Liver Transpl, 17 (2011), pp. 896-904
[12.]
M. Aguilar-Guisado, J. Gavaldà, P. Ussetti, A. Ramos, P. Morales, M. Blanes, et al.
Pneumonia after lung transplantation in the Resitra Cohort: a multicenter prospective study.
Am J Transplant, 7 (2007), pp. 1989-1996
[13.]
J. Torre-Cisneros, C. Herrero, E. Cañas, J.M. Reguera, M. De la Mata, M.A. Gómez-Bravo.
Bacteremia after liver transplantation in the SAEI cohort: high mortality related with Staphylococcus aureus.
Eur J Clin Microbiol Infect Dis, 21 (2002), pp. 385-388
[14.]
C. Garzoni, The AST Infectious Diseases Community of Practice.
Multiply resistant gram-positive bacteria methicillin-resistant, vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus (MRSA, VISA, VRSA) in solid organ transplant recipients.
Am J Tansplant, 9 (2009), pp. S41-S49
[15.]
G. Santoro-Lopes, E.F. De Gouvea, R.C. Monteiro, R.C. Branco, J.R. Rocco, M. Halpern, et al.
Colonization with methicillin-resistant Staphylococcus aureus after liver transplantation.
Liver Transpl, 11 (2005), pp. 203-209
[16.]
N. Singh, C. Squier, C. Wannstedt, L. Keyes, M.M. Wagener, T.V. Cacciarelli.
Impact of an aggressive infection control strategy on endemic Staphylococcus aureus infection in liver transplant recipients.
Infect Control Hosp Epidemiol, 27 (2006), pp. 122-126
[17.]
N. Singh, D.L. Paterson, F.Y. Chang, T. Gayowski, C. Squier, M.M. Wagener, et al.
Methicillin-resistant Staphylococcus aureus: the other emerging resistant grampositive coccus among liver transplant recipients.
Clin Infect Dis, 30 (2000), pp. 322-327
[18.]
F. Bert, J.O. Galdbart, V. Zarrouk, J. Le Mée, F. Durand, F. Mentré, et al.
Association between nasal carriage of Staphylococcus aureus and infection in liver transplant recipients.
Clin Infect Dis, 31 (2000), pp. 1295-1299
[19.]
D. Desai, N. Desai, P. Nightingale, T. Elliott, J. Neuberger.
Carriage of methicillinresistant Staphylococcus aureus is associated with an increased risk of infection after liver transplantation.
Liver Transpl, 9 (2003), pp. 754-759
[20.]
D.L. Russell, A. Flood, T.E. Zaroda, C. Acosta, M.M. Riley, R.W. Busuttil, et al.
Outcomes of colonization with MRSA and VRE among liver transplant candidates and recipients.
Am J Transplant, 8 (2008), pp. 1737-1743
[21.]
O.A. Adeyemi, C. Qi, T.R. Zembower, M.G. Ison, T.H. Grant, B.J. Hartigan, et al.
Invasive infections with community-associated methicillin-resistant Staphylococcus aureus after kidney transplantation.
J Clin Microbiol, 46 (2008), pp. 2809-2813
[22.]
A. Obed, A.A. Schnitzbauer, T. Bein, N. Lehn, H.J. Linde, H.J. Schlitt.
Fatal pneumonia caused by Panton-Valentine Leucocidine-positive methicillin-resistant Staphylococcus aureus (PVL-MRSA) transmitted from a healthy donor in living-donor liver transplantation.
Transplantation, 81 (2006), pp. 121-124
[23.]
F. Bert, J. Clarissou, F. Durand, D. Delefosse, C. Chauvet, P. Lefebrve, et al.
Prevalence, molecular epidemiology, and clinical significance of heterogeneous glycopeptides intermediate Staphylococcus aureus in liver transplant recipients.
J Clin Microbiol, 41 (2003), pp. 5147-5152
[24.]
S.A. McNeil, P.N. Malani, C.E. Chenoweth, R.J. Fontana, J.C. Magee, J.D. Punch, et al.
Vancomycin-resistant enterococcal colonization and infection in liver transplant candidates and recipients: a prospective surveillance study.
Clin Infect Dis, 42 (2006), pp. 195-203
[25.]
P. Muñoz, The AST Infectious Diseases Community Practice.
Multiply resistant gram-positive bacteria: vancomycin. resistant Enterococcus in solid organ transplantation.
Am J Transplant, 9 (2009), pp. S50-S56
[26.]
E. González-Barca, A. Fernández-Sevilla, J. Carratalà, A. Grañena, F. Gudiol.
Prospective study of 288 episodes of bacteremia in neutropenic cancer patients in a single institution.
Eur J Clin Microbiol Infect Dis, 15 (1996), pp. 291-296
[27.]
C. Cordonnier, A. Buzin, G. Leverger, R. Herbrecht, M. Hunnault, R. Leclercq, et al.
Epidemiology and risk factors for gram-positive coccal infections in neutropenia: toward a more targeted antibiotic strategy.
Clin Infect Dis, 36 (2003), pp. 149-158
[28.]
R. Ramphal.
Changes in the etiology of bacteremia in febrile neutropenic patients and the susceptibilities of the currently isolated pathogens.
Clin Infect Dis, 39 (2004), pp. S25-S31
[29.]
L.S. Elting, G.P. Bodey, B.H. Keefe.
Septicemia and shock syndrome due to viridans streptococci: a case-control study of predisposing factors.
Clin Infect Dis, 14 (1992), pp. 1201-1207
[30.]
R.M. Prabhuv, K.E. Piper, M.R. Litzow, J.M. Steckelberg, R. Patel.
Emergence of quinolone resistance among viridans group streptococci isolated from the oropharynx of neutropenic peripheral blood stem cell transplant patients receiving quinolone antimicrobial prophylaxis.
Eur J Clin Microbiol Infect Dis, 24 (2005), pp. 832-838
[31.]
C.Y. Chen, W. Tsay, J.L. Tang, H.F. Tien, Y.C. Chen, S.C. Chang, et al.
Epidemiology of bloodstream infections in patients with haematological malignancies with and without neutropenia.
Epidemiol Infect, 138 (2010), pp. 1044-1051
[32.]
B.A. Collin, H.L. Leather, J.R. Wingard, R. Ramphal.
Evolution, incidence, and susceptibility of bacterial bloodstream isolates from 519 bone marrow transplant patients.
Clin Infect Dis, 33 (2001), pp. 947-953
[33.]
D. Engelhard, H. Elishoov, N. Strauss, E. Naparstek, A. Nagler, A. Simhon, et al.
Nosocomial coagulase-negative staphylococcal infections in bone marrow transplantation recipients with central vein catheter. A 5-year prospective study.
Transplantation, 61 (1996), pp. 430-434
[34.]
S.F. Costa, A.A. Barone, M.H. Miceli, I.M. Van der Heijden, R.E. Soares, A.S. Levin, et al.
Colonization and molecular epidemiology of coagulase-negative staphylococcal bacteremia in cancer patients: a pilot study.
Am J Infect Control, 34 (2006), pp. 36-40
[35.]
A.R. Tunkel, K.A. Sepkowitz.
Infections caused by viridans streptococci in patients with neutropenia.
Clin Infect Dis, 34 (2002), pp. 1524-1529
[36.]
A. Marron, J. Carratalà, E. González-Barca, A. Fernández-Sevilla, F. Alcaide, F. Gudiol.
Serious complications of bacteremia caused by viridans streptococci in neutropenic patients with cancer.
Clin Infect Dis, 31 (2000), pp. 1126-1130
[37.]
J. Carratalà, F. Alcaide, A. Fernández-Sevilla, X. Corbella, J. Liñares, F. Gudiol.
Bacteremia due to viridans streptococci that are highly resistant to penicillin: increase among neutropenic patients with cancer.
Clin Infect Dis, 20 (1995), pp. 1169-1173
[38.]
A. Marron, J. Carratalà, F. Alcaide, A. Fernández-Sevilla, F. Gudiol.
High rates of resistance to cephalosporins among viridans-group streptococci causing bacteraemia in neutropenic cancer patients.
J Antimicrob Chemother, 47 (2001), pp. 87-91
[39.]
W.T. Huang, L.Y. Chang, P.R. Hsueh, C.Y. Lu, P.L. Shao, F.Y. Huang, et al.
Clinical features and complications of viridans streptococci bloodstream infection in pediatric hemato-oncology patients.
J Microbiol Immunol Infect, 40 (2007), pp. 349-354
[40.]
M.A. Montecalvo, H. Horowitz, C. Gedris, C. Carbonaro, F.C. Tenover, A. Issah, et al.
Outbreak of vancomycin-, ampicillin-, and aminoglycoside-resistant Enterococcus faecium bacteremia in an adult oncology unit.
Antimicrob Agents Chemother, 38 (1994), pp. 1363-1367
[41.]
A. Marron, J. Carratalà, J. Ayats, A. Fernández-Sevilla, M.A. Domínguez, J. Liñares, et al.
Bacteriemia por enterococos resistentes a vancomicina en los pacientes neutropénicos con cáncer.
Med Clin (Barc), 111 (1998), pp. 761-764
[42.]
J.B. Bossaer, P.D. Hall, E. Garrett-Mayer.
Incidence of vancomycin-resistant enterococci (VRE) infection in high-risk febrile neutropenic patients colonized with VRE.
Support Care Cancer, 19 (2011), pp. 231-237
[43.]
E. González-Barca, J. Carratalà, A. Mykietiuk, A. Fernández-Sevilla, F. Gudiol.
Predisposing factors and outcome of Staphylococcus aureus bacteremia in neutropenic patients with cancer.
Eur J Clin Microbiol Infect Dis, 20 (2001), pp. 117-119
[44.]
M. Falcone, A. Micozzi, M.E. Pompeo, P. Baiocchi, F. Fabi, A. Penni, et al.
Methicilliresistant staphylococcal bacteremia in patients with hematologic malignancies: clinical and microbiological retrospective comparative analysis of S. haemolyticus, S. epidermidis, and S. aureus.
J Chemother, 16 (2004), pp. 540-548
[45.]
S.I. Cuervo, J.A. Cortés, R. Sánchez, J.Y. Rodríguez, E. Silva, D. Tibavizco, et al.
Risk factors for mortality caused by Staphylococcus aureus bacteremia in cancer patients.
Enferm Infecc Microbiol Clin, 28 (2010), pp. 349-354
[46.]
J. Carratalà, B. Rosón, A. Fernández-Sevilla, F. Alcaide, F. Gudiol.
Bacteremic pneumonia in neutropenic patients with cancer. Causes, empirical antibiotic therapy, and outcome.
Arch Intern Med, 158 (1998), pp. 868-872
[47.]
J. Carratalà, A. Marron, A. Fernández-Sevilla, J. Liñares, F. Gudiol.
Treatment of penicillin-resistant pneumococcal bacteremia in neutropenic patients with cancer.
Clin Infect Dis, 24 (1997), pp. 148-152
[48.]
H. Van der Lelie, M. Leverstein-Van Hall, M. Mertens, H.C.T. Van Zaanen, R.H.J. Van Oers, B.L.M. Thomas, et al.
Corynebacterium CDC group JK (Corynebacterium jeikeium) sepsis in haematological patients: a report of three cases and systematic literature review.
Scand J Infect Dis, 27 (1995), pp. 581-584
[49.]
A. Jucglà, G. Sais, J. Carratalà, A. Moreno, A. Fernández-Sevilla, J. Peyri.
A papular eruption secondary to infection with Corynebacterium jeikeium, with histopathological features mimicking botryomycosis.
Br J Dermatol, 133 (1995), pp. 801-804
[50.]
H.S. Sader, T.R. Fritsche, R.N. Jones.
Frequency of ocurrence and daptomycin susceptibility rates of gram-positive organisms causing bloodstream infections in cancer patients.
J Chemother, 20 (2008), pp. 570-576
[51.]
H.S. Sader, A.A. Watters, T.R. Fritsche, R.N. Jones.
Daptomycin antimicrobial activity tested against methicillin-resistant staphylococci and vancomycin-resistant enterococci isolated in European medical centers (2005).
BMC Infectious Diseases, 7 (2007), pp. 29
[52.]
C. Kratzer, W. Rabitsch, A.M. Hirschl, W. Graninger, E. Presteri.
In vitro activity of daptomycin and tigecycline against coagulase-negative staphylococcus blood isolates from bone marrow transplant recipients.
Eur J Haematol, 79 (2007), pp. 405-409
[53.]
H.S. Sader, D.J. Farrell, R.N. Jones.
Antimicrobial activity of daptomycin tested against gram-positive strains collected in European hospitals: results from 7 years of resistance surveillance (2003–2009).
J Chemother, 23 (2011), pp. 200-206
[54.]
F.Y. Chang, J.E. Peacock Jr., D.M. Musher, P. Triplett, B.B. MacDonald, J.M. Mylotte, et al.
Staphylococcus aureus bacteremia: recurrence and the impact of antibiotic treatment in a prospective multicenter study.
Medicine (Baltimore), 82 (2003), pp. 333-339
[55.]
A. Commetta, W.V. Kern, R. De Bock, M. Paesmans, M. Vandenbergh, F. Crokaert, et al.
Vancomycin versus placebo for treating persistent fever in patients with neutropenic cancer receiving piperacillin-tazobactam monotherapy.
Clin Infect Dis, 37 (2003), pp. 382-389
[56.]
R.G. Wunderink, J. Rello, S.K. Cammarata, R.V. Croos-Dabrera, M.H. Kollef.
Linezolid vs vancomycin: analylis of two double-blind studies of patients with methicillinresistant Staphylococcus aureus nosocomial pneumonia.
Chest, 124 (2003), pp. 1789-1797
[57.]
B. Jaksic, G. Martinelli, J. Pérez-Oteyza, C.S. Hartman, L.B. Leonard, K.J. Tack.
Efficacy and safety of linezolid compared with vancomycin in a randomized, double-blind study of febrile neutropenic patients with cancer.
Clin Infect Dis, 42 (2006), pp. 597-607
[58.]
C. Liu, A. Bayer, S.E. Cosgrove, R.S. Daum, S.K. Fridkin, R.J. Gorwitz, et al.
Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary.
Clin Infect Dis, 52 (2011), pp. 285-292
[59.]
V.G. Fowler Jr., H.W. Boucher, G.R. Corey, E. Abrutyn, A.W. Karchmer, M.E. Rupp, et al.
Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus.
N Engl J Med, 355 (2006), pp. 653-665
[60.]
D.A. Figueroa, E. Mangini, M. Amodio-Groton, B. Verdianos, A. Melchert, C. Fana, et al.
Safety of highdose intravenous daptomycin treatment: three-year cumulative experience in a clinical program.
Clin Infect Dis, 49 (2009), pp. 177-180
[61.]
B.A. Mueller, J.A. Crompton, B.J. Donovan, S. Yankalev, K.C. Lamp.
Safety of daptomycin in patients receiving hemodialysis.
Pharmacotherapy, 31 (2011), pp. 665-672
[62.]
G.R. Barber, J. Lauretta, R. Sáez.
A febrile neutropenic patient with Enterococcus gallinarum sepsis treated with daptomycin and gentamicin.
Pharmacotherapy, 27 (2007), pp. 927-932
[63.]
D.D. Poutsiaka, S. Skiffington, K.B. Miller, S. Hadley, D.R. Snydman.
Daptomycin in the treatment of vancomycin-resistant Enterococcus faecium bacteremia in neutropenic patients.
J Infect, 54 (2007), pp. 567-571
[64.]
K.A. Mergenhagen, M.T. Pasko.
Daptomycin use after vancomycin-induced neutropenia in a patient with left-sided endocarditis.
Ann Pharmacother, 41 (2007), pp. 1531-1535
[65.]
K.V. Rolston, S.A. McConnell, J. Brown, K.C. Lamp.
Daptomycin use in patients with cancer and neutropenia: data from a retrospective registry.
Clin Adv Hematol Oncol, 8 (2010), pp. 249-256
[66.]
A.M. Chaftari, R. Hachem, V. Mulanovich, R.F. Chemaly, J. Adachi, K. Jacobson, et al.
Efficacy and safety of daptomycin in the treatment of Gram-positive catheterrelated bloodstream infections in cancer patients.
Int J Antimicrob Agents, 62 (2010), pp. 182-186
[67.]
S. Kraft, E. Mackler, P. Schlickman, K. Welch, D.D. Depestel.
Outcomes of therapy: vancomycin-resistant enterococcal bacteremia in hematology and bone marrow transplant patients.
Support Care Cancer, 19 (2011), pp. 1969-1974
[68.]
M. Kamboj, N. Cohen, K. Gilhuley, N.E. Babady, S.K. Seo, K.A. Sepkowitz.
Emergence of daptomycin-resistant VRE: experience of a single institution.
Infect Control Hosp Epidemiol, 32 (2011), pp. 391-394
[69.]
S. Vernadakis, F.H. Saner, P.M. Rath, G.M. Kaiser, Z. Mathe, J. Treckmann, et al.
Successful salvage therapy with daptomycin after linezolid and vancomycin failure in a liver transplant recipient with methicillin-resistant Staphylococcus aureus endocarditis.
Transpl Infect Dis, 1 (2009), pp. 346-348
[70.]
O. Len, J. Gavaldà, C. Cervera, M. Montejo, A. Arnaiz, N. Fernández-Sabé, et al.
Daptomycin in the treatment of Gram-positive cocci in solid organ transplantation.
50th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology,
Copyright © 2012. Elsevier España S.L.. Todos los derechos reservados
Opciones de artículo
Herramientas
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos

es en pt
Política de cookies Cookies policy Política de cookies
Utilizamos cookies propias y de terceros para mejorar nuestros servicios y mostrarle publicidad relacionada con sus preferencias mediante el análisis de sus hábitos de navegación. Si continua navegando, consideramos que acepta su uso. Puede cambiar la configuración u obtener más información aquí. To improve our services and products, we use "cookies" (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here. Utilizamos cookies próprios e de terceiros para melhorar nossos serviços e mostrar publicidade relacionada às suas preferências, analisando seus hábitos de navegação. Se continuar a navegar, consideramos que aceita o seu uso. Você pode alterar a configuração ou obter mais informações aqui.